Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
23.90
+0.24 (1.01%)
At close: Sep 4, 2026, 4:00 PM EDT
23.90
0.00 (0.00%)
After-hours: Sep 4, 2026, 4:00 PM EDT
Arcutis Biotherapeutics Revenue
Arcutis Biotherapeutics had revenue of $129.86M in the quarter ending June 30, 2026, with 59.33% growth. This brings the company's revenue in the last twelve months to $463.98M, up 76.11% year-over-year. In the year 2025, Arcutis Biotherapeutics had annual revenue of $376.07M with 91.34% growth.
Revenue (ttm)
$463.98M
Revenue Growth
+76.11%
P/S Ratio
6.47
Revenue / Employee
$1,310,681
Employees
354
Market Cap
3.00B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 376.07M | 179.53M | 91.34% |
| Dec 31, 2024 | 196.54M | 136.94M | 229.74% |
| Dec 31, 2023 | 59.61M | 55.92M | 1,517.09% |
| Dec 31, 2022 | 3.69M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Tarsus Pharmaceuticals | 606.33M |
| Zai Lab | 449.61M |
| Beam Therapeutics | 156.04M |
| Nurix Therapeutics | 36.77M |
| uniQure | 18.67M |
| NewAmsterdam Pharma Company | 7.12M |
| AtaiBeckley | 4.47M |
| Immunome | 4.02M |
ARQT News
- 2 days ago - Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - GlobeNewsWire
- 3 days ago - Arcutis Biotherapeutics Slides: Corporate presentation - Filings
- 11 days ago - Oruka Therapeutics appoints Todd Edwards as chief commercial officer - TheFly
- 4 weeks ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Arcutis Biotherapeutics price target raised to $38 from $34 at Morgan Stanley - TheFly
- 4 weeks ago - Arcutis Biotherapeutics price target raised to $36 from $35 at Mizuho - TheFly
- 4 weeks ago - Arcutis Biotherapeutics price target raised to $38 from $35 at Guggenheim - TheFly
- 4 weeks ago - Arcutis Biotherapeutics Earnings Call Transcript: Q2 2026 - Transcripts